Selank + DSIP (Dream State) research monograph — the anxiolytic-plus-sleep neuropeptide blend

Selank + DSIP ("Dream State") is a vendor blend of two neuropeptides — Selank (an anxiolytic tuftsin analogue) and DSIP (Delta Sleep-Inducing Peptide) — marketed together for calm and sleep.

Class

Blend of two neuropeptides: Selank (anxiolytic) + DSIP (sleep-related). Blend compound.

Mechanism

The two components act through mechanistically distinct pathways. Selank is a synthetic heptapeptide analogue of the immunopeptide tuftsin; it stabilizes enkephalins and produces GABAergic and serotonergic modulation with reduced hypothalamic-pituitary-adrenal (HPA) axis activation, reported to give anxiolysis without sedation, and associated with raised BDNF in anxiety research from the Institute of Molecular Genetics in Moscow. DSIP is a naturally occurring nonapeptide (first isolated in 1977) with pleiotropic effects including delta-wave sleep induction, circadian and neuroendocrine (HPA) normalization, and antioxidant activity. The blend's rationale is dual-pathway: anxiolysis from Selank plus sleep induction from DSIP, addressing the stress-and-insomnia loop together.

Research summary

The combination is mechanistically complementary, but there are no controlled studies of the blend itself — "synergy" claims are vendor or secondary-source, not trial data. Each component individually is studied mostly in Russian and animal research; DSIP's human sleep literature in particular is old and mixed. Indexed grounding for the blend is thin (three general peptide-review documents).

Studied protocols

No blend-specific protocol exists. Community practice uses each component's informal dosing (Selank intranasally or subcutaneously; DSIP subcutaneously at night). These reflect community practice, not research-validated dosing.

Stacking research

The blend is itself the stack; there are no controlled data on the pairing. See the individual Selank and DSIP monographs for component-level grounding.

Clinical / safety context

Neither component is FDA/EMA-approved; both are sold research-use-only. There are no combination safety data, and component safety derives largely from Russian and animal research.

Evidence quality — Limited

The mechanisms are complementary, but the combination is unstudied and the component evidence is preclinical and regional.

Notes

"Dream State" = Selank + DSIP. Cross-reference the standalone Selank and DSIP monographs; this entry covers the rationale for combining them, not their individual records.